poly(ADP-ribose) polymerase family member 4 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PARP4P2 profile across patient tissues and cancer cell-line models. PARP4P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PARP4P2 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, PARP4P2 RNA expression shows 15,069 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LIHC, and UVM as cancer lineages where PARP4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP4P2 survival associations across molecular data types. PARP4P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP4P2 RNA expression–survival associations across cancer types. High PARP4P2 expression shows unfavorable associations in LGG and ESCA, but favorable associations in HNSC, ACC, READ and THCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for PARP4P2 RNA expression.
This table summarizes PARP4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PARP4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP4P2 shows lower tumor expression in KICH, BRCA and READ and higher tumor expression in LIHC, CHOL and KIRC. The LIHC box plot shows higher PARP4P2 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p < 0.001).
This table shows molecular features associated with PARP4P2 in patient tissues and cancer cell lines. In patient samples, PARP4P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
